Filing Details
- Accession Number:
- 0001599901-24-000040
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-12 17:29:35
- Reporting Period:
- 2024-03-08
- Accepted Time:
- 2024-03-12 17:29:35
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1599901 | Avidity Biosciences Inc. | RNA | Pharmaceutical Preparations (2834) | 461336960 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1629383 | Sarah Boyce | C/O Avidity Biosciences, Inc. 10578 Science Center Drive, Suite 125 San Diego CA 92121 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-03-08 | 84,000 | $1.24 | 196,117 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-03-08 | 84,000 | $21.39 | 112,117 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-03-12 | 28,000 | $1.24 | 140,117 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-03-12 | 28,000 | $22.63 | 112,117 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-03-08 | 84,000 | $0.00 | 84,000 | $1.24 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-03-12 | 28,000 | $0.00 | 28,000 | $1.24 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 929,015 | 2029-12-17 | No | 4 | M | Direct | |
| 901,015 | 2029-12-17 | No | 4 | M | Direct |
Footnotes
- Includes the following securities previously acquired by the Reporting Person: (i) 107,408 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan.
- This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.33 to $21.54. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.61 to $22.71. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- All unexercised shares subject to the option are fully vested and exercisable as of the date hereof.
Billionaire Hedge Funds
